drugset
drugset / Trial / NCT05870423

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

NCT05870423 ↗

Phase 1 Recruiting 24 enrolled Erasmus Medical Center
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives, efficacy, pharmacokinetics and biomarker response will be investigated.

Timeline

Start
2022-06-01
Primary completion
2027-01-01
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 50 mg —
Subject Olaparib Small molecule 100 mg —
Subject Olaparib Small molecule 200 mg —
Subject Olaparib Small molecule 300 mg —

Indications

neuroendocrine neoplasm